Parkinson's Disease - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Parkinson's Disease - Pipeline Review, H1 2018’, provides an overview of the Parkinson's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Parkinson's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Parkinson's Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Parkinson's Disease

The report reviews pipeline therapeutics for Parkinson's Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Parkinson's Disease therapeutics and enlists all their major and minor projects

The report assesses Parkinson's Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Parkinson's Disease

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Parkinson's Disease

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Parkinson's Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

AC Immune SA

Acorda Therapeutics Inc

Addex Therapeutics Ltd

Aeolus Pharmaceuticals Inc

Affichem SA

AFFiRiS AG

AlfaSigma SpA

Allergan Plc

Amabiotics SAS

Amarantus ...

AbbVie Inc

AC Immune SA

Acorda Therapeutics Inc

Addex Therapeutics Ltd

Aeolus Pharmaceuticals Inc

Affichem SA

AFFiRiS AG

AlfaSigma SpA

Allergan Plc

Amabiotics SAS

Amarantus Bioscience Holdings Inc

American Gene Technologies International Inc

Amneal Pharmaceuticals Inc

Anavex Life Sciences Corp

Antoxis Ltd

Aoxing Pharmaceutical Company Inc

APeT Holding BV

ApoPharma Inc

Araclon Biotech SL

ArmaGen Inc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Auritec Pharmaceuticals Inc

AVM Biotechnology LLC

Axovant Sciences Ltd

Bactevo Ltd

Berg LLC

Bial - Portela & Ca SA

Bio-Modeling Systems SAS

BioArctic AB

BioElectron Technology Corp

Biogen Inc

BioHealthonomics Inc

Biopharm GmbH

Blackthorn Therapeutics Inc

BlueRock Therapeutics

BrainStorm Cell Therapeutics Inc

C4X Discovery Holdings PLC

Calico LLC

Cantabio Pharmaceuticals Inc

Cardax Inc

Carmot Therapeutics Inc

Carna Biosciences Inc

Cavion LLC

Cellix Bio Pvt Ltd

CHA Bio & Diostech Co Ltd

Chipscreen Biosciences Ltd

Clera Inc

Clevexel Pharma SAS

Copernicus Therapeutics Inc

Corium International Inc

Crossject SA

Curemark LLC

Daewoong Pharmaceutical Co Ltd

Denali Therapeutics Inc

Diffusion Pharmaceuticals Inc

Dizlin Medical Design AB

Domain Therapeutics SA

Easywell Biomedical Inc

Eli Lilly and Co

Energenesis Biomedical Co Ltd

Evgen Pharma Plc

Fabre-Kramer Pharmaceuticals Inc

Forma Therapeutics Inc

FPRT Bio Inc

Fulcrum Therapeutics Inc

Genecode AS

Generon (Shanghai) Corp Ltd

Genervon Biopharmaceuticals LLC

GenKyoTex SA

Genmab A/S

Genosco Inc

Genzyme Corp

H. Lundbeck AS

Hanmi Pharmaceuticals Co Ltd

Hemostemix Inc

Heptares Therapeutics Ltd

Herantis Pharma Plc

Hisamitsu Pharmaceutical Co Inc

HitGen LTD

ICB International Inc

Icure Pharmaceutical Inc

ID Pharma Co Ltd

Immungenetics AG

Impel NeuroPharma Inc

India Globalization Capital Inc

InnoMedica Holding AG

Intec Pharma Ltd

International Stem Cell Corp

Intra-Cellular Therapies Inc

Io Therapeutics Inc

Ionis Pharmaceuticals Inc

IRLAB Therapeutics AB

Jeil Pharmaceutical Co Ltd

Kainos Medicine Inc

Khondrion BV

Kissei Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Living Cell Technologies Ltd

Longevity Biotech Inc

Luye Pharma Group Ltd

M et P Pharma AG

M's Science Corp

M3 Biotechnology Inc

MedGenesis Therapeutix Inc

MedImmune LLC

Merck & Co Inc

Merz Pharma GmbH & Co KgaA

Metabolic Solutions Development Company LLC

MimeTech Srl

Minerva Neurosciences Inc

Mission Therapeutics Ltd

Mitochon Pharmaceuticals Inc

Montisera Ltd

Motac Neuroscience Ltd

Neonc Technologies Inc

Netherlands Translational Research Center BV

Neuren Pharmaceuticals Ltd

NeuroDerm Ltd

Neurodyn Life Sciences Inc

NeuroGeneration Inc

NeuroNascent Inc

NeurOp Inc

Neuropore Therapies Inc

New World Laboratories Inc

Newron Pharmaceuticals SpA

nLife Therapeutics SL

Novartis AG

Novo Nordisk AS

Omeros Corp

Oncodesign SA

OPKO Health Inc

OptiNose US Inc

Orion Corporation

Oryzon Genomics SA

Oxford BioMedica Plc

ParkCell AB

Parkure Ltd

Peptron Inc

Pfizer Inc

Pharma Two B Ltd

Pharmicell Co Ltd

Pharnext SA

Phenomenome Discoveries Inc

Phoenix Biotechnology Inc

Plex Pharmaceuticals Inc

Prana Biotechnology Ltd

Priavoid GmbH

ProMIS Neurosciences Inc

Promius Pharma LLC

Prosetta Biosciences Inc

Prothena Corp Plc

QR Pharma Inc

reMYND NV

Rich Pharmaceuticals Inc

Sage Therapeutics Inc

SanBio Inc

Saniona AB

Sanofi

Serina Therapeutics Inc

Shire Plc

SignPath Pharma Inc

SK Biopharmaceuticals Co Ltd

STATegics Inc

Stealth BioTherapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sunovion Pharmaceuticals Inc

Synthonics Inc

Takara Bio Inc

TechnoPhage SA

Teikoku Pharma USA Inc

Teva Pharmaceutical Industries Ltd

Titan Pharmaceuticals Inc

UCB SA

UniQure NV

Varinel Inc

Voyager Therapeutics Inc

vTv Therapeutics Inc

Xoc Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 10

Parkinson's Disease - Overview 11

Parkinson's Disease - Therapeutics Development 12

Parkinson's Disease - Therapeutics Assessment ...

Table of Contents

Table of Contents 2

Introduction 10

Parkinson's Disease - Overview 11

Parkinson's Disease - Therapeutics Development 12

Parkinson's Disease - Therapeutics Assessment 55

Parkinson's Disease - Companies Involved in Therapeutics Development 75

Parkinson's Disease - Drug Profiles 152

Parkinson's Disease - Dormant Projects 809

Parkinson's Disease - Discontinued Products 828

Parkinson's Disease - Product Development Milestones 830

Appendix 840

List of Tables

List of Tables

Number of Products under Development for Parkinson's Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Tables

Number of Products under Development for Parkinson's Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Parkinson's Disease - Pipeline by AbbVie Inc, H1 2018

Parkinson's Disease - Pipeline by AC Immune SA, H1 2018

Parkinson's Disease - Pipeline by Acorda Therapeutics Inc, H1 2018

Parkinson's Disease - Pipeline by Addex Therapeutics Ltd, H1 2018

Parkinson's Disease - Pipeline by Aeolus Pharmaceuticals Inc, H1 2018

Parkinson's Disease - Pipeline by Affichem SA, H1 2018

Parkinson's Disease - Pipeline by AFFiRiS AG, H1 2018

Parkinson's Disease - Pipeline by AlfaSigma SpA, H1 2018

Parkinson's Disease - Pipeline by Allergan Plc, H1 2018

Parkinson's Disease - Pipeline by Amabiotics SAS, H1 2018

Parkinson's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Parkinson's Disease - Pipeline by American Gene Technologies International Inc, H1 2018

Parkinson's Disease - Pipeline by Amneal Pharmaceuticals Inc, H1 2018

Parkinson's Disease - Pipeline by Anavex Life Sciences Corp, H1 2018

Parkinson's Disease - Pipeline by Antoxis Ltd, H1 2018

Parkinson's Disease - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2018

Parkinson's Disease - Pipeline by APeT Holding BV, H1 2018

Parkinson's Disease - Pipeline by ApoPharma Inc, H1 2018

Parkinson's Disease - Pipeline by Araclon Biotech SL, H1 2018

List of Figures

List of Figures

Number of Products under Development for Parkinson's Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Parkinson's Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports